Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
I am Intramural Blog

Antibiotics Could Assist Liver Cancer Care

Four Questions with Dr. Tim Greten

By Brooke Worthing

Tuesday, November 19, 2019

medications

IRP research led by Dr. Tim Greten suggests that antibiotics could be a useful tool in the fight against liver cancer.

There are over 100 different types of cancer, with liver, breast, and colon cancers among the most common. At the NIH, researchers across the organization have long been committed to furthering cancer research in an effort to increase the number of cancer survivors. They consistently push the boundaries of this field each day in the hopes that their work could lead to better diagnoses, better treatment, and better outcomes for cancer patients.

A 2018 study by IRP senior investigator Tim Greten, M.D., and his IRP colleagues did just that and more. Their research pushed the norms of cancer research by studying how a treatment as simple as antibiotics affects cancerous liver tumors. By utilizing antibiotics to wipe out the collection of microorganisms living in the digestive tracts of mice — known as the gut microbiome — the team identified a link between the gut microbiome and the behavior of the liver’s immune cells, which play a role in defending the organ against cancer. The IRP team ultimately showed that antibiotic treatment reduced the development of liver tumors in these ‘germ-free’ mice, and it also reduced the likelihood that tumors in other areas of the body would metastasize — or spread — to the animals’ livers, a finding that could one day prove beneficial to future cancer patients.

In recognition of National Antibiotic Awareness Week this week, I spoke with Dr. Greten to explore why he was interested in studying the impact antibiotics might have on cancerous tumors, what collaborations were important in this study, and how he is expanding on his research today.

What prompted you to study the impact of antibiotics on cancerous tumors?

“When I first read about cancer researchers who were studying the gut microbiome, I couldn’t believe what I was reading. It seemed bizarre to me. However, it was from reading about these studies and the work of other researchers that I began thinking about the potential of the gut microbiome myself. I really began this research out of pure curiosity.

“As a physician, I see patients with cancer fairly often and I didn’t want to believe that something as simple as antibiotics could have such a profound impact on tumor growth. As we all know, chemotherapy and radiation therapy are very advanced, commonly used treatments for cancer. However, through our study, we were all of a sudden seeing that antibiotics could change the gut microbiome and produce surprising effects on tumor growth. It’s amazing but it almost seems too simple.”

What was the most challenging aspect of this study?

Dr. Tim Greten

Dr. Tim Greten

“We faced a number of challenges when conducting this study. Notably, in order to test the link between the gut microbiome and the effectiveness of cancer treatments, the first experiment we conducted was to confirm the impact of antibiotic treatment. The ideal scenario is to perform this research in germ-free mice, which are mice that have no microorganisms living in or on them. As one can imagine, germ-free mice need special housing to ensure that they stay germ-free, which is very difficult to execute. At the time, we did not have easy access to the support we needed to successfully utilize these germ-free mice, which were essential to our study. After quite a lot of preparation and perseverance, I was able to obtain approval for my team to conduct its planned experiments with germ-free mice.

“Another challenge we faced were the study criteria required by the journal's review team. The reviewers required that we prove that we had the ability to colonize, or infect, mice with a single type of bacteria that would reverse antibiotics' inhibitory effect on tumor growth. From an experimental point of view, this was very difficult to do, as there are a number of challenges to overcome in order to prove this. It took us quite a bit of time to do so.”

What collaborations were important in conducting this research?

“There were three very important collaborations that contributed to this study. First was the pivotal collaboration with Giorgio Trinchieri, and his group at the NIH’s National Cancer Institute. Giorgio is a true expert in the microbiome and helped my team study the germ-free mice and conduct bacterial DNA sequencing, which were both essential to our research. It was an extremely helpful collaboration as these were not our areas of expertise at all. 

“The second key collaboration happened by happenstance. When we first began this research, we had no idea that immune cells called NKT cells — cells that share properties of both T cells and natural killer cells — would play such an important role in this system we were studying. Through our research, we found that NKT cells were the cells that would ultimately inhibit tumors from forming in the liver. By chance, I had been participating in joint lab meetings with another intramural investigator, Jay Berzofsky, who happened to be an expert in NKT cells. Once we realized that these cells played a role in the system, it was instrumental to tap into Jay’s expertise.

“The third collaboration, which was also extremely valuable, was with another intramural investigator, Xin Wei Wang . At the time of our study, Xin Wei had already created a database filled with metabolic data from human livers from one of his own cohort studies in patients with liver tumors. Since he already had data on liver tissue and bile acid readily available, we were able to use those data for our confirmatory studies in humans, which was unbelievably helpful.”

What impact has this research had on the field to-date and what are your plans for the future?

“To be honest, I don’t think that this research has had a direct impact on cancer research or cancer care as of yet. At this point in time, I believe it is too early to see such a result, but we will see! With that said, for our group at the NIH and our own experiments, this research has had a huge impact on our focus of study.

“Following the initial study in germ-free mice, our group began expanding upon the work in a number of follow-up studies on the topic. Based on the original study, we now have an ongoing clinical trial where we’re hoping to investigate the experimental questions addressed in our previous animal studies now in patients, as opposed to mice. We want to see if mechanisms similar to those we discovered in mice can apply to patients, and also investigate whether antibiotic treatment, in collaboration with other drugs, can reduce primary and metastatic liver tumors in human patients.” 

Head over to our Accomplishments page for more information on Dr. Segre and Dr. Kong’s research, and subscribe to our weekly newsletter to stay up-to-date on the latest breakthroughs in the NIH Intramural Research Program.


Category: IRP Discoveries
Tags: accomplishments, antibiotics. microbiome, cancer, liver, bacteria, immune system

Related Blog Posts

  • Dying Tumor Cells Suppress Anti-Cancer Immune Response
  • Creating Cutting-Edge Cancer Vaccines
  • Poster Sessions Celebrate Summer Science
  • African Ancestry May Influence Immune Response to Prostate Cancer
  • Leveraging Turncoat Immune Cells to Combat Cancer

This page was last updated on Tuesday, January 30, 2024

Blog menu

  • Contributing Authors
    • Anindita Ray
    • Brandon Levy
    • Devon Valera
    • Melissa Glim
  • Categories
    • IRP Discoveries
    • Profiles
    • Events
    • NIH History
    • IRP Life

Blog links

  • Subscribe to RSS feed

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search